ArticleFrontiers in nephrology2025
Reflective versus predictive value of urinary podocin, nephrin, and their ratio in diabetic kidney disease: a 12-month retrospective cohort study.
Article in Frontiers in nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dynamics and Predictive Values of Urinary Podocyte Biomarkers Following SGLT2 Inhibition in CKD.Life (Basel, Switzerland) · 2026Article
- Clinical Determinants of Urinary Podocyte Biomarkers and Their Feasibility in Paraprotein-Related Kidney Disease.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Podocyte injury plays a central role in the development of diabetic kidney disease (DKD). Urinary podocin, nephrin, and the podocin-nephrin ratio (PNR) have been proposed as early indicators of glomerular injury, but their prognostic value remains uncertain. This study aimed to evaluate whether baseline urinary podocyte biomarkers reflect current disease severity and predict DKD progression. Methods: We conducted a retrospective cohort study involving 119 adults with type 2 diabetes and DKD. Baseline urinary podocin, nephrin, and PNR were measured using ELISA. Kidney outcomes were assessed over 12 months. DKD progression was defined as ≥5 mL/min/1.73 m² decline in estimated glomerular filtration rate (eGFR) and/or ≥30% increase in urine albumin-creatinine ratio (uACR). Follow-up uACR data were available for 52 participants. ROC analyses evaluated predictive performance. Results: At baseline, median eGFR was 68.1 mL/min/1.73 m² and median uACR was 112 mg/g. Over 12 months, eGFR declined significantly, while uACR showed high variability without consistent change. Among participants with complete outcome data, 19 (36.5%) experienced eGFR decline and 17 (32.7%) showed uACR progression. Baseline podocin, nephrin, and PNR were numerically higher in progressors but showed no significant group differences (all p > 0.3). Predictive performance was poor: AUCs for eGFR decline were 0.504 (podocin), 0.512 (nephrin), and 0.523 (PNR). For albuminuria progression, AUCs were 0.563, 0.524, and 0.544, respectively. Subgroup analyses similarly showed no significant predictive value. Discussion: These results suggest that single baseline measurements of podocin, nephrin, or PNR may have limited short-term prognostic value in DKD. However, the presence of these markers, even in patients with only moderate disease, supports their role as early indicators of podocyte stress. Conclusion: While urinary podocyte-associated proteins reflect early glomerular injury, their utility as stand-alone prognostic biomarkers over a one-year period may be limited. Larger longitudinal studies assessing biomarker trajectories and integrating additional molecular markers are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.